Aravive Inc (ARAV) Stock Price, Quote, News and Overview
NASDAQ:ARAV - Nasdaq - US03890D1081 - Common Stock - Currency: USD
ARAV Quote, Performance and Key Statistics
0.0401
-0.01 (-13.39%)
The current stock price of ARAV is 0.0401 USD. In the past month the price decreased by -68.84%. In the past year, price decreased by -97.76%.
ARAV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ARAV
Company Profile
Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The firm's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Company Info
Aravive Inc
River Oaks Tower, 3730 Kirby Drive, Suite 1200
Houston TEXAS 77098 US
CEO: Gail McIntyre
Employees: 23
Company Website: https://aravive.com/
Phone: 19363551910
Aravive Inc / ARAV FAQ
What is the stock price of Aravive Inc today?
The current stock price of ARAV is 0.0401 USD. The price decreased by -13.39% in the last trading session.
What is the ticker symbol for Aravive Inc stock?
The exchange symbol of Aravive Inc is ARAV and it is listed on the Nasdaq exchange.
On which exchange is ARAV stock listed?
ARAV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Aravive Inc stock?
6 analysts have analysed ARAV and the average price target is 0.26 USD. This implies a price increase of 535.91% is expected in the next year compared to the current price of 0.0401. Check the Aravive Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Aravive Inc worth?
Aravive Inc (ARAV) has a market capitalization of 2.95M USD. This makes ARAV a Nano Cap stock.
How many employees does Aravive Inc have?
Aravive Inc (ARAV) currently has 23 employees.
Is Aravive Inc (ARAV) expected to grow?
The Revenue of Aravive Inc (ARAV) is expected to decline by -38.62% in the next year. Check the estimates tab for more information on the ARAV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Aravive Inc (ARAV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARAV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARAV, evaluating the profitability, health, valuation and growth aspects
- Aravive Inc (ARAV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Aravive Inc (ARAV) Sales and EPS estimates to see what analysts future expectations are.
- Aravive Inc (ARAV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Aravive Inc (ARAV) Insider and Institutional Ownership to learn about the owners and their transactions.
- Aravive Inc (ARAV) Stock Chart to make your own analysis
- Aravive Inc (ARAV) Latest news and press-releases to stay up to date.
Does Aravive Inc (ARAV) stock pay dividends?
ARAV does not pay a dividend.
When does Aravive Inc (ARAV) report earnings?
Aravive Inc (ARAV) will report earnings on 2024-03-13, after the market close.
What is the Price/Earnings (PE) ratio of Aravive Inc (ARAV)?
Aravive Inc (ARAV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).
ARAV Technical Analysis
ARAV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARAV. While ARAV seems to be doing ok healthwise, there are quite some concerns on its profitability.
ARAV Financial Highlights
Over the last trailing twelve months ARAV reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 59.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -306.54% | ||
| ROE | -2344.12% | ||
| Debt/Equity | 0 |
ARAV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ARAV. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 90.73% and a revenue growth -38.62% for ARAV